Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

141. Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials

Efficacy and safety of bivalirudin versus heparin in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO

142. Bleeding risk in low-molecular-weight-heparin (LMWH)-treated patients with severe renal insufficiency: a meta-analysis

Bleeding risk in low-molecular-weight-heparin (LMWH)-treated patients with severe renal insufficiency: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2015 PROSPERO

143. Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy

Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Article

2015 Evidence-Based Medicine

144. PROPATEN heparin-bonded vascular graft for peripheral arterial disease

PROPATEN heparin-bonded vascular graft for peripheral arterial disease PR PROP OPA ATEN heparin-bonded vascular gr TEN heparin-bonded vascular graft for aft for peripher peripheral arterial disease al arterial disease Medtech innovation briefing Published: 13 October 2015 nice.org.uk/guidance/mib42 pathways Summary Summary The Gore PROPATEN heparin-bonded vascular graft is a synthetic graft used to treat peripheral arterial disease by bypassing damaged blood vessels. The graft is made from (...) expanded polytetrafluoroethylene (ePTFE) that has a layer of heparin anticoagulant bonded to its inner surface, which is designed to reduce graft occlusion. Relevant evidence was limited and consisted of 1 randomised controlled trial and 5 cohort studies, with either artificial graft or autologous vein graft comparators. The reports indicate that the PROPATEN graft is either equivalent or inferior to autologous vein grafts in maintaining patency (that is, remaining open and functional over time

2015 National Institute for Health and Clinical Excellence - Advice

145. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial Full Text available with Trip Pro

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial Venous thromboembolism (VTE) is common in cancer patients. Evidence has suggested that low molecular weight heparin (LMWH) might improve survival in patients with cancer by preventing both VTE and the progression of metastases. No trial in a single cancer type has been powered to demonstrate a clinically significant survival difference. The aim of this trial

2015 EvidenceUpdates Controlled trial quality: predicted high

146. Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study Full Text available with Trip Pro

Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings

2014 EvidenceUpdates Controlled trial quality: uncertain

147. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Full Text available with Trip Pro

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference (...) in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin.To evaluate the comparative cost-effectiveness of LMWH vs UFH for prophylaxis against VTE in critically ill patients.Prospective economic evaluation concurrent with the Prophylaxis for Thromboembolism in Critical Care Randomized Trial (May 2006 to June 2010). The economic evaluation adopted a health care payer

2014 JAMA

148. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. (Abstract)

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based anticoagulation regimen compared with a heparin-based anticoagulation regimen on ischaemic and bleeding outcomes.We searched Medline, the Cochrane Library, and relevant meeting abstracts (search done (...) on April 9, 2014) for randomised trials that assessed bivalirudin versus heparin in patients planned for PCI. The primary efficacy endpoint was the incidence of major adverse cardiac events (MACE) up to 30 days. Secondary efficacy endpoints were death, myocardial infarction, ischaemia-driven revascularisation, and stent thrombosis. The primary safety endpoint was major bleeding up to 30 days. We calculated pooled risk ratios and 95% CIs using random-effects models.We included data from 16 trials

2014 Lancet

149. Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. (Abstract)

Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. Heparin is an anticoagulant medication that is normally injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma and pain at the injection site. One of the factors that may affect pain, haematoma and bruising is injection speed.To assess the effects of the duration (speed) of subcutaneous heparin injection on pain, haematoma (...) and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin or low molecular weight heparin.The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). We searched MEDLINE, EMBASE, CINAHL and two Persian databases Iranmedex and SID (August 2013).We sought randomised controlled trials (RCTs) comparing the effects of different durations

2014 Cochrane

150. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Full Text available with Trip Pro

Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the chance of live birth in subsequent pregnancies in women with unexplained recurrent miscarriage, with or without inherited thrombophilia.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two (...) , unfractionated heparin (UFH), and low molecular weight heparin (LMWH) for the prevention of miscarriage. One treatment could be compared with another or with no-treatment (or placebo).Two review authors (PJ and SK) assessed the studies for inclusion in the review and extracted the data. If necessary they contacted study authors for more information. We double checked the data.Nine studies, including data of 1228 women, were included in the review evaluating the effect of either LMWH (enoxaparin or nadroparin

2014 Cochrane

151. Heparin versus placebo for non-ST elevation acute coronary syndromes. Full Text available with Trip Pro

Heparin versus placebo for non-ST elevation acute coronary syndromes. Non-ST elevation acute coronary syndromes (NSTEACS) represent a spectrum of disease including unstable angina and non-ST segment myocardial infarction (NSTEMI). Despite treatment with aspirin, beta-blockers and nitroglycerin, unstable angina/NSTEMI is still associated with significant morbidity and mortality. Although evidence suggests that low molecular weight heparin (LMWH) is more efficacious compared to unfractionated (...) heparin (UFH), there is limited data to support the role of heparins as a drug class in the treatment of NSTEACS. This is an update of a review last published in 2008.To determine the effect of heparins (UFH and LMWH) compared with placebo for the treatment of patients with non-ST elevation acute coronary syndromes (unstable angina or NSTEMI).For this update the Cochrane Heart Group Trials Search Co-ordinator searched the Cochrane Central Register of Controlled Trials on The Cochrane Library (2013

2014 Cochrane

152. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Full Text available with Trip Pro

Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. The choice of the appropriate perioperative thromboprophylaxis in patients with cancer depends on the relative benefits and harms of low molecular weight heparin (LMWH) and unfractionated heparin (UFH).To update a systematic review of the evidence for the relative efficacy and safety of LMWH and UFH for perioperative thromboprophylaxis in patients with cancer.We performed (...) ), postoperative drain volume (MD= 27mL; 95% CI -44 to 98), and thrombocytopenia (RR 1.33; 95% CI 0.59 to 3.00).We found no difference between perioperative thromboprophylaxis with LMWH versus UFH in their effects on mortality, thromboembolic outcomes, major bleeding, or minor bleeding in patients with cancer. Further trials are needed to evaluate the benefits and harms of different heparin thromboprophylaxis strategies in this population more thoroughly.

2014 Cochrane

153. Heparin versus normal saline for patency of arterial lines. Full Text available with Trip Pro

Heparin versus normal saline for patency of arterial lines. For most patients who require intensive care, the success of clinical decision making and interventions is dependent on the accuracy of different physiological variables measured or obtained from samples using an arterial catheter. Maintaining the patency of these catheters is therefore essential for obtaining accurate measures, minimizing patient discomfort and reducing expenses incurred when an occluded catheter requires replacement (...) . Uncertainty exists amongst clinicians as to best practice surrounding the contents of the arterial catheter flush solution (heparin or saline). The use of heparin is more expensive and is accompanied by significant risks such as haemorrhage, hypersensitivity and heparin-induced thrombocytopenia (HIT).The objective of this review was to evaluate whether normal saline is as efficacious and safe as heparin in maintaining the patency of arterial intravascular catheters in adult patients without

2014 Cochrane

154. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. (Abstract)

Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Anticoagulant treatment for intermittent claudication might improve functional capacity and prevent acute cardiovascular complications caused by peripheral obstructive arterial disease. This is an update of the review first published in 2001.To assess the effects of anticoagulant drugs (heparin, low molecular weight heparin (LMWH) and oral anticoagulants) in patients with intermittent (...) patients with intermittent claudication.Seven studies were included. Only three studies (two evaluating oral anticoagulants, one evaluating heparin) met the high quality methodological inclusion criteria and were included in the primary analysis. Four other studies were included in the sensitivity analysis. The authors extracted the data independently.No new studies were included for this update. Seven studies with a combined total of 802 participants were included in this review. No significant

2014 Cochrane

155. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Full Text available with Trip Pro

Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Venous thromboembolic disease has been extensively studied in surgical patients. The benefit of thromboprophylaxis is now generally accepted, but it is medical patients who make up the greater proportion of the hospital population. Medical patients differ from surgical patients with regard to their health and the pathogenesis of thromboembolism and the impact (...) that preventative measures can have. The extensive experience from thromboprophylaxis studies in surgical patients is therefore not necessarily applicable to non-surgical patients. This is an update of a review first published in 2009.To determine the effectiveness and safety of heparin (unfractionated heparin or low molecular weight heparin) thromboprophylaxis in acutely ill medical patients admitted to hospital, excluding those admitted to hospital with an acute myocardial infarction or stroke (ischaemic

2014 Cochrane

156. Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty

Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty Record Status This is a bibliographic record (...) of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Portable pneumatic compression versus low-molecular-weight heparin for prevention of deep vein thrombosis after lower-extremity joint arthroplasty. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2014 Authors' conclusions Deep vein thrombosis (DVT) is a blood clot, or thrombus, that forms in a deep vein most commonly in the legs. DVT is serious since

2014 Health Technology Assessment (HTA) Database.

157. Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. (Abstract)

Low molecular weight heparin for prevention of central venous catheterization-related thrombosis in children. The prevalence of children diagnosed with deep vein thrombosis or pulmonary embolism has been increasing in the last decade. The most common thrombosis risk factor in neonates, infants and children is the placement of a central venous catheter (CVC). To date, it is unknown if the practice of anticoagulation prophylaxis with low molecular weight heparin (LMWH) decreases CVC-related

2014 Cochrane

158. Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization. (Abstract)

Different unfractionated heparin doses for preventing arterial thrombosis in children undergoing cardiac catheterization. The role of cardiac catheterization in pediatrics has progressed significantly over the last two decades, evolving from a primary diagnostic tool to a primary treatment modality in children with congenital heart disease. Vascular complications, particularly arterial thrombosis, are among the most common unwanted post-cardiac catheterization events. In 1974, unfractionated (...) heparin proved to be superior to placebo in decreasing the incidence of arterial thrombosis in pediatric patients. However, the optimal dose of unfractionated heparin to be utilized in this setting remains a matter of controversy.To evaluate the use of low-dose (< 100 units/kg) versus high-dose (≥ 100 units/kg) unfractionated heparin administered as an intravenous bolus at the time of initiation of cardiac catheterization (that is, immediately after arterial puncture), with or without subsequent

2014 Cochrane

159. Heparin-bonded catheters for prolonging the patency of central venous catheters in children. (Abstract)

Heparin-bonded catheters for prolonging the patency of central venous catheters in children. Central venous catheters (CVCs) are a mainstay in the management of critically ill children. However, these catheters are associated with mechanical and infectious complications which reduce their life span. Heparin bonding of catheters has shown promise in animal studies and in adults. This is the first update of a review published in 2007.The primary objective was to determine the effect of heparin (...) -bonded CVCs on the duration of catheter patency in children. Secondary objectives were to determine the effects of heparin-bonded catheters on catheter-related thrombosis, occlusion, blood stream infection and side effects.For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). The authors searched MEDLINE (1946 to week 3 August 2013).We included randomized and quasi

2014 Cochrane

160. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism (...) : a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

2014 Health Technology Assessment (HTA) Database.